Twist Bioscience CEO sells 45,736 shares for taxes
The sales had different stated mechanics: one followed a June 2026 trading plan, while the other covered tax withholding from Restricted Stock Unit vesting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Twist Bioscience Corp (TWST) reported two direct common-stock sales by Chief Executive Officer Emily M. Leproust: 655 shares on October 1, 2026, at $200.0000 per share under a Rule 10b5-1 plan adopted June 15, 2026; and 45,736 shares on October 2, 2026, at $188.8840 per share to cover tax withholding from Restricted Stock Unit vesting. The latter sale was mandated under the issuer’s equity incentive plans and was not discretionary. She also reported options covering 131,290 common shares at a $23.3300 exercise price, expiring October 23, 2029, and 64,950 common shares at a $67.8500 exercise price, expiring August 31, 2030.
Insights
Analyzing...
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F2 | 45,736 | $188.884 | $8.64M |
| Sale | Common Stock F1 | 655 | $200.00 | $131K |
| holding | Employee Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F4 | -- | -- | -- |
Footnotes (4)
- F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
- F2. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F3. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F4. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
sell to cover financial
Restricted Stock Units financial
performance stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What vesting terms are reported for Emily M. Leproust’s TWST options?
AI-generated analysis. How Rhea-AI works. Not financial advice.